Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: Evaluation of efficacy and toxicity

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 492-496

  Okuma, Yusuke ^a   Hosomi, Yukio ^a   Takagi, Yusuke ^a   Iguchi, Mari ^a   Okamura, Tatsuru ^a   Shibuya, Masahiko ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Cisplatin; First line chemotherapy; Irinotecan hydrochloride; Metastasis; Thymic carcinoma

Indexed keywords

AMRUBICIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; THYMUS CANCER; THYMUS CARCINOMA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; CISPLATIN; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; THYMUS NEOPLASMS; TREATMENT OUTCOME;

EID: 80755132140     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.05.013     Document Type: Article

References (32)

1. Eng T.Y., Fuller C.D., Jagirdar J., Bains Y., Thomas C.R. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004, 59:654-664.
2. Shimosato Y., Kameya T., Nagai K., Suemasu K. Squamous cell carcinoma of the thymus. An analysis of eight cases. Am J Surg Pathol 1977, 1:109-121.
3. Travis W.D.B.W., Müller-Hermelink H.K., Harris C.C. World Health Organization classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart 2004, IARC Press, Lyon, [Chapter 3].
4. Yoh K., Goto K., Ishii G., Niho S., Ohmatsu H., Kubota K., et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 2003, 98:926-931.
5. Murray N., Shah A., Osoba D., Page R., Karsai H., Grafton C., et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 1991, 9:1632-1638.
6. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85-91.
7. Koga K., Matsuno Y., Noguchi M., Mukai K., Asamura H., Goya T., et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 1994, 44:359-367.
8. Rosai J., Sobin L. Histological typing of tumors of the thymus. WHO International Histological Classification of Tumours 1999, Springer-Verlag, Berlin, Heidelberg. 2nd ed.
9. Muller-Hermelink H.K., Marino M., Palestro G. Pathology of thymic epithelial tumors. Curr Top Pathol 1986, 75:207-268.
10. Okumura M., Ohta M., Tateyama H., Nakagawa K., Matsumura A., Maeda H., et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002, 94:624-632.
11. Quintanilla-Martinez L., Wilkins E.W., Choi N., Efird J., Hug E., Harris N.L. Thymoma. Histologic subclassification is an independent prognostic factor. Cancer 1994, 74:606-617.
12. Levine G.D., Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol 1978, 9:495-515.
13. Suster S., Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 1991, 67:1025-1032.
14. Petrini I, Zucali PA, Lee HS, Pineda MA, Meltzer PS, Walter-Rodriguez B, et al. Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol;5:1447-53.
15. Koizumi T., Takabayashi Y., Yamagishi S., Tsushima K., Takamizawa A., Tsukadaira A., et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 2002, 25:266-268.
16. Loehrer P.J., Kim K., Aisner S.C., Livingston R., Einhorn L.H., Johnson D., et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994, 12:1164-1168.
17. Magois E., Guigay J., Blancard P.S., Margery J., Milleron B., Lher P., et al. Multimodal treatment of thymic carcinoma: report of nine cases. Lung Cancer 2008, 59:126-132.
18. Fuse E.T., Kamimura M., Takeda Y., Kawaishi M., Kimura S., Niino H., et al. Response of a thymic mucoepidermoid carcinoma to combination chemotherapy with cisplatin and irinotecan: a case report. Lung Cancer 2008, 59:403-406.
19. Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol, 2011;29:2060-5.
20. Igawa S., Murakami H., Takahashi T., Nakamura Y., Tsuya A., Naito T., et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 2010, 67:194-197.
21. Strobel P., Hartmann M., Jakob A., Mikesch K., Brink I., Dirnhofer S., et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004, 350:2625-2626.
22. Strobel P., Bargou R., Wolff A., Spitzer D., Manegold C., Dimitrakopoulou-Strauss A., et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010, 103:196-200.
23. Li X.F., Chen Q., Huang W.X., Ye Y.B. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 2009, 26:157-160.
24. Pedersini R., Vattemi E., Lusso M.R., Mazzoleni G., Ebner H., Graiff C. Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: a case report. Tumori 2008, 94:849-852.
25. Oberg K., Kvols L., Caplin M., Delle Fave G., de Herder W., Rindi G., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15:966-973.
26. Oguri T., Achiwa H., Kato D., Maeda H., Niimi T., Sato S., et al. Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy 2004, 50:279-282.
27. Hsu C.H., Yeh K.H., Cheng A.L. Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin. Anticancer Res 1997, 17:1331-1334.
28. Igawa S., Murakami H., Yamamoto N. Thymic small cell carcinoma shows marked response to amrubicin. J Thorac Oncol 2009, 4:778.
29. Okuma Y., Shimokawa T., Takagi Y., Hosomi Y., Iguchi M., Okamura T., et al. S-1 is an active anticancer agent for advanced thymic carcinoma. Lung Cancer 2010, 70:357-363.
30. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18:317-323.
31. Gidron A., Quadrini M., Dimov N., Argiris A. Malignant thymoma associated with fatal myocarditis and polymyositis in a 32-year-old woman with a history of hairy cell leukemia. Am J Clin Oncol 2006, 29:213-214.
32. Komatsu Y., Koizumi T., Tanabe T., Hatayama O., Yasuo M., Okada M., et al. Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma - three cases. Anticancer Res 2006, 26:4851-4855.